Novartis urges First Circuit not to revive sham litigation claim

A lower court correctly held that Novartis’s patent litigation against a generic drugmaker was not objectively baseless or motivated by anticompetitive intent, the pharmaceutical company told the US Court of Appeals for the First Circuit on Monday.